Michael C. Donegan - Jan 23, 2023 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
Prin. Fin. and Acctg. Officer
Signature
/s/ Michael C. Donegan
Stock symbol
TXMD
Transactions as of
Jan 23, 2023
Transactions value $
-$6,988
Form type
4
Date filed
1/25/2023, 04:50 PM
Previous filing
Dec 9, 2022
Next filing
Jan 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise $0 +380 +8.34% $0.00 4.93K Jan 23, 2023 Direct F1
transaction TXMD Common Stock Options Exercise $0 +1.07K +21.61% $0.00 6K Jan 23, 2023 Direct F1
transaction TXMD Common Stock Options Exercise $0 +519 +8.65% $0.00 6.52K Jan 23, 2023 Direct F1
transaction TXMD Common Stock Options Exercise $0 +2.4K +36.82% $0.00 8.92K Jan 23, 2023 Direct F1
transaction TXMD Common Stock Sale -$6.95K -1.3K -14.6% $5.34 7.62K Jan 23, 2023 Direct F2, F3
transaction TXMD Common Stock Sale -$37 -7 -0.09% $5.31 7.61K Jan 24, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Options Exercise $0 -380 -100% $0.00* 0 Jan 23, 2023 Common Stock 380 $0.00 Direct F1, F4
transaction TXMD Restricted Stock Units Options Exercise $0 -1.07K -100% $0.00* 0 Jan 23, 2023 Common Stock 1.07K $0.00 Direct F1, F5
transaction TXMD Restricted Stock Units Options Exercise $0 -519 -100% $0.00* 0 Jan 23, 2023 Common Stock 519 $0.00 Direct F1, F6
transaction TXMD Restricted Stock Units Options Exercise $0 -2.4K -100% $0.00* 0 Jan 23, 2023 Common Stock 2.4K $0.00 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4 The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
F5 The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
F6 Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
F7 The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".